|
Post by mnkdfann on Jan 4, 2017 11:26:54 GMT -5
Forget about their job functions for a second. On a personal level, would you join a company you thought was at risk of bankruptcy within 6 months? I probably wouldn't (unless I was getting close to retirement and the company offered big bucks), but it happens all the time. I know someone who left a well paying job to move to a company that lost over 97% of its value last year. I won't name the company, but you've heard of it. It is in the pharma sector. Many (most) people are predicting this company's demise in the very near future. Even the person I know who moved there does not think it will last. So why did he switch jobs? He said he moved because the people there are friendlier, the work environment is nicer, the hours are better, the commute is shorter, and he has a bunch of friends from a previous job at a different company now working there.
|
|
|
Post by buyitonsale on Jan 4, 2017 11:27:56 GMT -5
Now, let's try to spin "global biopharmaceutical company"
|
|
|
Post by agedhippie on Jan 4, 2017 11:29:02 GMT -5
Forget about their job functions for a second. On a personal level, would you join a company you thought was at risk of bankruptcy within 6 months? Bingo! big winner here. No you would not leave a job like that to go to a sinking ship. To leave Amgen you might Nobody here has any idea why he moved. We would like to think it's for a huge opportunity that he sees with Mannkind. It may also be because Amgen sucks as a workplace (according to a friend who left recently), maybe he was laid off, maybe Mannkind offered him a lot of money. It may be a permutation of these. I never see moves in general as an endorsement of any company. I couldn't care less about his motives, all I care about is that he delivers value for money - what has he done for me today?
|
|
|
Post by mango on Jan 4, 2017 11:29:58 GMT -5
We Just Hired a Chief People Officer (Why You Should, Too) January 13, 2014 • 1,355 Likes • 273 Comments Last week, my company hit a great milestone on the talent front: we hired our first Chief People Officer. Granted, it’s a title with the potential of sounding a little precious, like the “Vice President of Happiness,” “Brand Evangelist,” “Digital Overlord” or other Silicon Valley labels that dress up what are really garden-variety gigs. But the Chief People Officer position isn’t a rote, phone-it-in role – nor is it a cutesy name for the traditional human resources function. It’s a strategic shift in how we think about people, culture and enterprise value over the long term at a company. It’s about redefining culture so it’s not jellybeans, Nerf guns and free lunch. At Reputation.com, we certainly like those things but candy and eats alone don’t drive enterprise value. In my mind, culture is actually about the three or four aspects that are unique to your company that can be leveraged into business success. Here are some of the other reasons we’re convinced we need a Chief People Officer (and why you do too): You need more than traditional HR, which centers on people, process and policies. These are important aspects and they need to get done. But a CPO’s focus should be on building culture – facilitating an environment that enables the best possible way of working. And while Human Resources falls under the Chief People Officer, calling the CPO an HR person is like thinking of your Chief Financial Officer as an accountant. They play in the same space but the strategic focus is completely different. A CPO will reset the definition of culture with you. Chief People Officers understand that culture doesn’t equal happiness. (Note: happiness can certainly be the byproduct of a great culture). But too often, we equate culture with lifestyle and perks, the ephemeral fun stuff that makes up the bulk of articles on companies with the “greatest cultures.” In reality, perks are the nice-to-haves. There’s nothing wrong with them but the foundation of a culture rests on business goals, not masseuses and organic meals made to order. It’s asking, what can we do to identify, attract and retain the talent we need to drive enterprise value? Chief People Officers focus on the culture trifecta: people, value and capacity. They know it’s about who is working for you, the value they generate for the business, and what’s needed to turn that value up to its full capacity. Is it revamping the recruiting process so you hire people who feel a strong affinity for your mission? Is it coaching managers on how to inspire and reward employees? Is it exiting leaders who leach toxicity into your workplace? What changes, large and small, can you make to get to that capacity? thats fancy for a tech company with boatloads of $$$ and high share price like FB, google and other tech companies. For mannkind, its still vp of human resources. reading on stock twits - some one commented we need a chief patients officer.. lol and I agree It's not an officer postion, but nonetheless... • MannKind Corporation is currently seeking a Patient Advocate to support the company’s patient advocacy program by providing resources to patients. rew12.ultipro.com/MAN1011/JobBoard/JobDetails.aspx?__ID=*FF55BEE20CE43E33
|
|
|
Post by brotherm1 on Jan 4, 2017 11:57:59 GMT -5
Now, let's try to spin "global biopharmaceutical company" [br No spinning here. I wholeheartedly believe this to be true. The only thing different I heard before that is missing here is the word "BIG" biopharmaceutical company.
|
|
|
Post by careful2invest on Jan 4, 2017 12:13:07 GMT -5
MannKind Announces Key Addition to Its Executive Management Ranks VALENCIA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Stuart A. Tross, Ph.D., has joined the company as its Chief People Officer, with responsibilities for Human Resources, Information Technology and West Coast Facilities. Dr. Tross will be integral in accelerating the company's development into a world-class, global biopharmaceutical company centered on the value of its human capital. He will be reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKind's executive leadership team. Dr. Tross joins MannKind with several decades of leadership experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and Security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organization Psychology from the Georgia Institute of Technology. "To welcome Stuart to our executive management team, with his extensive biopharmaceutical background, is both timely and opportunistic. The addition of his wide-ranging experience will be transformational at MannKind," said Mr. Pfeffer. "Stuart's experience will not only facilitate a quick and efficient expansion of our Afrezza launch capability, but he will be instrumental in building an organization to accommodate other strategic initiatives, such as product development and global expansion." Dr. Tross commented, "I am excited to join the MannKind team during this time of rapid transformation. Afrezza is an innovative product in an area of unmet patient need with significant growth potential, and there are a number of additional growth opportunities in the pipeline. I look forward to contributing to MannKind's future." About MannKind Corporation MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the commercial potential of Afrezza. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, MannKind's ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2015 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. Well, Dr. Stuart Tross has quite an impressive resume! And typically, you do not quit a 10 year position, no matter the circumstances, to join a dead end company because the "people are nicer to work with" as someone stated! Dead end is dead end! MNKD is up and coming! Finally!! My favorite parts in these paragraphs below are where they use words like "quick and efficient expansion of AFREZZA launch", "global expansion" and "rapid transformation" Cut and pasted... "To welcome Stuart to our executive management team, with his extensive biopharmaceutical background, is both timely and opportunistic. The addition of his wide-ranging experience will be transformational at MannKind," said Mr. Pfeffer. "Stuart's experience will not only facilitate a quick and efficient expansion of our Afrezza launch capability, but he will be instrumental in building an organization to accommodate other strategic initiatives, such as product development and global expansion." Dr. Tross commented, "I am excited to join the MannKind team during this time of rapid transformation. Afrezza is an innovative product in an area of unmet patient need with significant growth potential, and there are a number of additional growth opportunities in the pipeline. I look forward to contributing to MannKind's future." Things are about to get better! GLTA TRUE LONGS!
|
|
|
Post by dreamboatcruise on Jan 4, 2017 12:15:39 GMT -5
Now, let's try to spin "global biopharmaceutical company" Which act of spinning are you referring to... acting like MNKD can never achieve it, or acting like mentioning it means it is inevitable.
|
|
|
Post by wgreystone on Jan 4, 2017 13:01:01 GMT -5
Will Amgen acquire MannKind soon?
|
|
|
Post by promann on Jan 4, 2017 13:03:38 GMT -5
Now, let's try to spin "global biopharmaceutical company" Which act of spinning are you referring to... acting like MNKD can never achieve it, or acting like mentioning it means it is inevitable. It might mean it's inevitable. And I truly believe it is..Lets see here the biggest reason that Diabetics are not staying on or getting Afrezza is because of cost. Well other countries may cover Afrezza with there health benefits the same as any other insulin so Afrezza may succeed better in them countries..
|
|
|
Post by buyitonsale on Jan 4, 2017 13:17:53 GMT -5
Everything that has been mentioned in the last CC is in the works. If any part of it is not going to happen, then management will comment and guide appropriately. It is evident that the company is now gearing toward international expansion as well. Get used to things progressing exactly as the management is telling us. The spinning I am referring to is trying to discredit the guidance and announcements from the management.
|
|
|
Post by mnkdnewbie on Jan 4, 2017 13:37:01 GMT -5
Will Amgen acquire MannKind soon? That was my first thought this morning when I read it, what position is needed most to transition staffing etc...
|
|
|
Post by sportsrancho on Jan 4, 2017 13:38:57 GMT -5
IMO there is no way they would over pay someone. Or lie to him to get him to jump on a sinking ship. IMO he came because of Afrezza! And I doubt he's worried. Just look at the people who don't seem worried.....And the ones who do....Where are they on the totem pole?
|
|
|
Post by snowballsmommy on Jan 4, 2017 13:45:51 GMT -5
Will Amgen acquire MannKind soon? WOW! My initial thought exactly. For all of you much smarter than I, your thoughts?
|
|
|
Post by afrezzamiracle on Jan 4, 2017 13:48:54 GMT -5
Amgen would certainly be in a power position to leverage the magic of the Technosphere drug/device inhaler patent portfolio.
|
|
|
Post by kc on Jan 4, 2017 13:50:59 GMT -5
based on public filing you can see that Stuart Tross had 25,671 shares of Amgen worth today about $3,914,827. you don't walk away from a good company to take a risk or flyer on a company that is on the brink of bankruptcy. So what is up other than speculation? www.nasdaq.com/quotes/insiders/tross-stuart-a-918546
|
|